Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Phase 1 on
ClassNone selected

Phase 1 included.

Clear filters

23 of 23 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

AstraZeneca 1

No dated milestone in 2025 to 2030

Ayala Pharmaceuticals 1

No dated milestone in 2025 to 2030

Cellestia Biotech 1

CB-103Phase 1/2
No dated milestone in 2025 to 2030

Dana-Farber Cancer Institute 1

No dated milestone in 2025 to 2030

Eisai (investigator studies) 1

No dated milestone in 2025 to 2030

Elevar Therapeutics 1

RivoceranibTrials stopped
No dated milestone in 2025 to 2030

Exelixis 1

No dated milestone in 2025 to 2030

Eye and ENT Hospital of Fudan University 1

No dated milestone in 2025 to 2030

HitGen 1

HG146Phase 2
No dated milestone in 2025 to 2030

Memorial Sloan Kettering 1

No dated milestone in 2025 to 2030

Memorial Sloan Kettering (investigator) 1

No dated milestone in 2025 to 2030

National Cancer Centre Singapore 1

No dated milestone in 2025 to 2030

National Cancer Institute 1

No dated milestone in 2025 to 2030

Novelty Nobility 1

NN3201Phase 1
No dated milestone in 2025 to 2030

Pfizer 1

No dated milestone in 2025 to 2030

Radboud UMC; Johns Hopkins (investigators) 1

No dated milestone in 2025 to 2030

Remix Therapeutics (merging with Passage Bio) 1

REM-422Phase 1/2
No dated milestone in 2025 to 2030

Rgenta Therapeutics 1

RGT-61159Phase 1
Phase 3 start (company plan), Q1 2027

Servier (registry sponsor Day One Biopharmaceuticals) 1

EMBLEM-1 first patients dosed, Oct 19, 2026

Shanghai Ninth People's Hospital 1

ApatinibPhase 2
No dated milestone in 2025 to 2030

Trisha Wise-Draper (investigator) 1

No dated milestone in 2025 to 2030

University of Michigan 1

No dated milestone in 2025 to 2030

VM Oncology 1

VMD-928Phase 1/2
No dated milestone in 2025 to 2030